Lupin receives FDA approval for SUPRAX® (Cefixime) Capsules, 400 mg NDA Approval to add to growing SUPRAX® Franchise ® - Lupin

BSE 2292.20 NSE 2288.50

indian flag icon

India

USA

great-britain flag icon

UK

south-africa flag icon

South Africa

australia flag icon

Australia

philippines flag icon

Philippines

germany flag icon

Germany

netherlands flag icon

Netherlands

mexico flag icon

Mexico

brazil flag icon

Brazil

canada flag icon

Canada

Switzerland flag icon

Switzerland

BSE 2292.20 NSE 2288.50

Lupin receives FDA approval for SUPRAX® (Cefixime) Capsules, 400 mg NDA Approval to add to growing SUPRAX® Franchise ®

June 5, 2012

-

Related Posts

February 5, 2026 Lupin Launches Topiramate Extended-Release Capsules in the United States
February 2, 2026 Lupin Launches Dasatinib Tablets in the United States
February 2, 2026 Lupin and TB Alliance Join Forces to Advance Telacebec for the Treatment of Tuberculosis and Other Mycobacterial Diseases

Search

Hit enter to search or ESC to close